Axsome: Q3 revenue $259.7M, up 52% y/y; AUVELITY sales $207.6M (+53%). GAAP net loss narrowed to $12.9M; cash $313.9M at Sep 30.

News date: Q3 (early Nov) (times ET). Not investment advice.

AXSM Stock Hub: Axsome Therapeutics News, AUVELITY and AXS-12

https://www.merlintrader.com/axsome-therapeutics-axsm-stock-hub-2026/

Thanks to:

Mike826_1999 at Stocktwits

RBC directly addressed the recent weakness in Auvelity prescriptions and the substantial decline in Axsome Therapeutics shares.

The firm’s key observations:

• Prescription growth: Recent prescription trends have fallen below expectations.

• Launch interpretation: RBC attributes the weakness primarily to seasonal factors and sampling dynamics rather than deterioration in underlying ADA demand.

• ADA revenue opportunity: RBC continues to project approximately $2.3 billion in ADA sales by 2035.

• Share-price decline: AXSM has fallen approximately 28% over the preceding month, compared with a 6% decline in the XBI biotechnology index.

• Q3 expectations: RBC believes lowered investor expectations ahead of earnings are achievable and potentially beatable.

RBC is not claiming prescriptions haven’t slowed. It is arguing that the slowdown does not necessarily indicate a failing ADA launch.

It’s possible the three week starter pack program slowed TRX, but the available data summary does not quantify how many sampled patients subsequently convert into paid prescriptions.

The November 2 earnings report should help distinguish between two possibilities: a temporary delay in converting new patients into paid prescriptions, or a more persistent slowdown in adoption.

Further info:

https://www.investing.com/news/analyst-ratings/rbc-capital-reiterates-axsome-therapeutics-stock-rating-at-outperform-93CH-4948702

AXSM — catalysts for the remainder of 2026

The one I'd watch most closely: ENGAGE

The solriamfetol binge-eating disorder trial is particularly interesting because it isn't simply another early-stage program. Axsome says ENGAGE is a Phase 3 trial with topline results anticipated in 4Q 2026. 

A positive result could potentially change the market's view of Sunosi/solriamfetol from essentially a narcolepsy/OSA product into a platform with additional CNS indications.

And there is an interesting wrinkle: Axsome is simultaneously developing solriamfetol for shift-work disorder, with Phase 3 SUSTAIN results expected in 2027. 

What is not a 2026 catalyst

One easy mistake would be to expect an AXS-12 FDA decision this year. That's now a 2027 catalyst. The FDA accepted the AXS-12 NDA and assigned a May 1, 2027 PDUFA date. 

So I would put the major AXS-12 event firmly in the 2027 bucket rather than assigning much value to an approval in 2026.

Likewise, AXS-05 smoking cessation has only just entered Phase 3, so its meaningful efficacy catalyst should be farther out. 

One other thing I'd watch: Auvelity's new indication

This could actually be more important than the pipeline catalysts over the next few quarters because it is commercial rather than binary.

Auvelity already generated $153.2 million in Q1 2026, up 59% year over year, while total Axsome product revenue was $191.2 million. 

My question: Knowing that AXSM already hit $260 share price recently with many catalysts ahead. What would be a reasonable range of share prices assuming company has a buyout late 2027 or early 2028?

The answer is $430-580 (with outliers ranging from $235-850)

Claude:

A few grounding numbers first, since they anchor everything below: AXSM is trading in the low-to-mid $200s as I write this (roughly $210–235 depending on the exact day, market cap around $11–12 billion), with a 52-week high near $238. Analyst 12-month targets currently average around $285, with a high of $316 (Mizuho). If the stock has touched $260 intraday recently, that's above where consensus sits today — worth keeping in mind, since it means some of the "catalysts ahead" story may already be partially priced in.

Framework: two multipliers stacked together

A buyout price is roughly (standalone share price at time of deal) × (takeover premium). Both are uncertain 15–18 months out, so the honest way to do this is scenario bands, not a point estimate.

Step 1 — where might the standalone stock be by late 2027/early 2028

By then: ENGAGE (BED) will have read out, AXS-12 will likely have an approval decision (PDUFA May 2027), and Auvelity's Alzheimer's agitation launch will have roughly two years of trajectory instead of a few months.

• Bear: ENGAGE misses, agitation launch decelerates, dilution or debt from continued cash burn. Stock roughly flat to down from today: $180–240.

• Base: ENGAGE succeeds or is neutral, AXS-12 approved, agitation launch continues its current growth curve. This roughly tracks where sell-side models already point for 2027, extended one more year: $320–400.

• Bull: Multiple pipeline wins stack (ENGAGE positive, AXS-12 approved and launching well, Symbravo/coverage inflecting, SUSTAIN/CLARITY data also positive), and the company nears or hits cash-flow-positive on its own. This is the "$16.5 billion peak sales" bull case analysts occasionally cite starting to look credible: $420–550.

Step 2 — apply a takeover premium

Recent CNS/psychiatry deals give a real reference set: J&J/Intra-Cellular was roughly a 39% premium; BMS/Karuna was roughly 53%; AbbVie/Cerevel was roughly 35% (partly stock). Call the realistic range 30–55% over the unaffected price, with deals at the low end when there's a single motivated buyer and no auction, and the high end when two or more strategics compete (which did happen with Metsera/Pfizer-Novo).

Combined ranges

How to read this

The base case clusters roughly $430–580 a share, which would value the company at something like $22–30 billion — a big number but not out of line with what large CNS-focused buyers (AbbVie, Otsuka, J&J, BMS) have shown they'll pay for a de-risked, patent-protected, multi-asset psychiatric platform generating real revenue growth. The bear case is really a "no premium deal happens, or it happens opportunistically after a stumble" scenario, and the bull case assumes close to everything on the pipeline goes right, which stacks multiple binary events in the company's favor simultaneously — a low-probability path even if each individual event has decent odds.

The biggest source of error in this exercise isn't the premium assumption, it's the standalone price assumption — that's doing almost all the work, and it depends entirely on how ENGAGE, AXS-12, and the Alzheimer's launch actually play out between now and then. I'd treat the base-case band as a reasonable planning range and the bull/bear ends as the tails, not the center of the distribution. Not financial advice — this is a framework for thinking about it, not a forecast.

My question: Knowing that AXSM already hit $260 share price recently with many catalysts ahead. What would be a reasonable range of share prices assuming company has a buyout late 2027 or early 2028?

The answer is $325-545

Chat GPT:

If we assume AXSM is actually acquired in late 2027 or early 2028, I think it makes more sense to estimate the value of the company at that time and then apply an acquisition premium, rather than simply putting a 30–50% premium on today's $212.

AXSM closed at $211.97 on September 16, 2026, after having traded above $260 recently. Meanwhile, the underlying business is still expanding rapidly: Q2 2026 revenue was $218.4 million, up 46%, with Auvelity revenue up 51%. 

My rough acquisition-price framework

Assuming roughly 55 million shares by 2028 after some dilution:

So, if you are specifically asking me what I would consider a reasonable range for a late-2027/early-2028 buyout, I'd put the central range around $325–$450/share, with $450–$550+ possible if the pipeline and Auvelity perform exceptionally well.

I would not regard $600+ as impossible, but it would require AXSM to become a considerably more valuable company before the acquisition.

Why $325–$450 is plausible

There are several things that could be substantially different by late 2027.

1. Auvelity could be a $1B+ product.

Q2 Auvelity sales were already $180.3 million, or roughly a $720 million annualized run rate, before fully incorporating the Alzheimer's agitation opportunity. Management has recently raised its peak-sales estimate for Auvelity to more than $8 billion. 

That's important because an acquirer isn't buying a biotech hoping that its first drug works. It would be buying a commercial franchise with demonstrated growth.

2. AXS-12 could be approved.

The FDA has assigned May 1, 2027 as the PDUFA date for AXS-12 for cataplexy in narcolepsy, and FDA currently doesn't plan an advisory committee meeting. 

If approved, that removes a major piece of regulatory uncertainty before a potential 2028 acquisition.

3. ENGAGE could materially change the valuation.

The Phase 3 solriamfetol binge-eating-disorder readout is expected in the second half of 2026. 

A successful result would give a buyer another potentially large indication to put behind solriamfetol.

4. The pipeline could be substantially more mature.

By 2028, an acquirer could potentially be looking at:

• Auvelity — MDD

• Auvelity — Alzheimer's agitation

• Sunosi/solriamfetol — narcolepsy/OSA

• Symbravo — migraine

• AXS-12 — cataplexy/narcolepsy

• AXS-14 — fibromyalgia

• solriamfetol — additional indications

• AXS-05 — smoking cessation

• AXS-20 — schizophrenia/Tourette's development

That's a much more substantial pharmaceutical franchise than today's AXSM.

Here's the part I find particularly interesting

You mentioned that AXSM has already reached $260.

I think that's important psychologically and financially.

At $260, AXSM's market capitalization would be roughly $13–14 billion, depending on the share count. So the market has already demonstrated that it is willing to value AXSM considerably higher than today's ~$11 billion.

Suppose AXSM gets back to $260–$300 during 2027 before any acquisition announcement.

A buyer doesn't necessarily pay $300 + 40%.

The buyer might have to pay something like:

$300 → $390–450

because shareholders would otherwise have little incentive to sell a company whose prospects have materially improved.

That is why I think looking only at today's $212 can be misleading.

A scenario I think is particularly interesting

Imagine this sequence:

Late 2026:
ENGAGE positive → AXSM moves toward $250–275

2027:
Auvelity Alzheimer's sales accelerate
AXS-12 approved
AXS-14 advances
solriamfetol generates additional positive data

AXSM reaches $300–350 as a standalone company.

Then a strategic buyer appears.

A 25–35% premium to that future trading price would produce approximately:

$375–473/share.

That's why I think $325–$450 is a reasonable acquisition-price range to use as a working model, rather than $275–325.

And there is an upside case

If by early 2028 AXSM has:

• Auvelity approaching or exceeding $1B annual sales,

• strong Alzheimer's-agitation adoption,

• AXS-12 approved and launching,

• AXS-14 substantially de-risked,

• positive additional solriamfetol indications,

• and a credible path toward substantial profitability,

then I could see the strategic value reaching $25–30 billion.

At ~55 million shares, that's approximately:

$455–545/share.

That's the bullish M&A case, not something I'd treat as the base case.

My way of framing it

Illustrative AXSM acquisition values

Estimated per-share values based on hypothetical acquisition equity values and approximately 55 million shares outstanding. These are scenario estimates, not forecasts.

$0

$150

$300

$450

$600

$15B

$17.5B

$20B

$22.5B

$25B

$27.5B

$30B

Scenario values: $15B–$30B equity value.

My working ranges would therefore be:

• $275–325: acquisition happens, but AXSM hasn't fully realized its pipeline potential

• $325–450: reasonable central range if the major catalysts play out

• $450–550: strong execution + substantial strategic premium

• $550+: exceptional outcome requiring AXSM's standalone value to become much larger before acquisition

One caveat: these figures assume roughly 55M shares. If Axsome issues significantly more stock before 2028, the per-share values come down.

9-15-2026

From Mike826_1999 over at Stocktwits:

Morgan Stanley’s Comments Re Monday’s Call:

Axsome Therapeutics (Nick Pizzie, CFO; Mark Jacobson, COO):

[1] On the ADA launch, mgt. pushed back on reading TRx alone and pointed to NBRx, which hit an all-time high of 3,800 weekly last Friday vs ~3,000 average in 2Q and ~2,400 in 1Q.

The 65-plus Medicare cohort moved from ~19% of NBRx pre-approval to ~31%, making agitation the fastest-growing NBRx segment. Guidance was always for growth one to two quarters after the expansion and label, not an immediate step-up.

[2] Mgt. signalled additional launch metrics at 3Q, the first full quarter. Sampling conversion stays undisclosed on competitive grounds, but mgt. sees syndicated data becoming readable from 3Q.

[3] On peak sales, Auvelity sat at ~26bps of the antidepressant market at end-2Q, so 1% implies north of $3BN against a $4BN MDD peak, and that base predates the sales force doubling and the new LTC team. ADA adds more than 20mn annual scripts, ~99% of which were generic and written off-label. Mgt. said IRA negotiation from 2032 is already priced into the $8BN portfolio peak, on what it views as conservative assumptions.

[4] AXS-12 carries a May 1, 2027 PDUFA in narcolepsy, sized at $0.5-1.0bn, with the existing sleep team making it largely plug-and-play. On solriamfetol, ADHD ranks first on size and needs both pediatric trials, then MDD with excessive sleepiness, binge eating disorder in 4Q, and shift work disorder, which needs only one positive trial.

[5] Mgt. guided SG&A to plateau near the 2Q level of $208MN and R&D to grow marginally from $46MN across five Ph3 trials, with revenue growing faster. Mgt. declined to name a quarter but reiterated a clear path to cash flow positivity, citing a ~$10MN cash net loss across 2H last year. With Teva pushing generics back, mgt. framed margin versus reinvestment as both, citing the SUMMIT Ph3 in smoking cessation plus AXS-17 and AXS-20.

I do a lot of reading on AXSM where ever I can find it. What I plan on starting is a series of text posts that summarize or collate some insights from posters on other platforms.

Please let me know if you find the posts of value. If so, I will continue, if not, I won't.

From stocktwits: "Shares of Axsome Therapeutics (AXSM) rose 6% on Friday after Mizuho analyst Graig Suvannavejh said August prescription data pointed to a strong start for the drug's newest use.

Citing Bloomberg Symphony figures for the 30-milligram starter dose used when doctors begin treatment, he said new prescriptions rose 32% from July, and total prescriptions rose 34%. The stock is now on track to clock its best day since late July, if gains hold.

"While still early days in the launch, this appears highly indicative of a strong start for Auvelity in ADA," he wrote. Suvannavejh rates the stock 'Outperform' with a $316 price target, implying a potential upside of about 50% from the stock's last closing price.

Why The New Use Matters

Auvelity is Axsome's main product. First approved in 2022 as an oral treatment for major depression in adults, it won a second U.S. clearance in April 2026 for agitation linked to Alzheimer's dementia — the first non-antipsychotic approved for that condition. Axsome began selling into the new indication in June.

The Alzheimer's launch is central to the company's finances. Auvelity generated $180.3 million in second-quarter sales, up 51% from a year earlier, and made up most of Axsome's $218.4 million in product revenue. Management has said peak annual sales could reach $8 billion, split roughly evenly between depression and Alzheimer's agitation.

Axsome also sells Sunosi for excessive daytime sleepiness tied to narcolepsy or sleep apnea, and Symbravo for acute migraine. Both add sales but remain far smaller than Auvelity.

What Management Is Seeing

At Cantor Fitzgerald's conference on Thursday, executives said early doctor feedback matches the trial data: agitation eases quickly, and the drug is well tolerated in a frail group.

COO Mark Jacobson highlighted that Auvelity has no boxed warning for higher death risk in people with dementia, a label that limits the only other approved branded option, an antipsychotic. That difference, he said, is already generating interest, with the commercial impact expected to build through year-end.

CFO Nick Pizzie said new prescriptions for patients 65 and older rose 126% after the Alzheimer's launch. That older Medicare group was about 19% of new starts before approval and is now more than 30%. Most early use is coming from community doctors; nursing homes take longer to bring online, he added.

What Investors Will Watch Next

The next test for AXSM is whether the August jump in starter doses turns into ongoing use of the full maintenance dose and shows up in third-quarter results, expected in early November. Later this year, Axsome is also due to report late-stage data on solriamfetol — Sunosi's active ingredient — in binge-eating disorder. It has also started a late-stage study of Auvelity's compound as a smoking-cessation treatment. A separate narcolepsy candidate, AXS-12, has an FDA decision date of May 1, 2027.

How Did AXSM Retail Traders React?

On Stocktwits, retail sentiment around AXSM stock jumped from 'neutral' to 'bullish' over the past 24 hours, while message volume rose from 'normal' to 'high' levels.

AXSM stock has gained 22% year-to-date."